Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer

Zhou, Haoxi; Gao, Yu; Liu, Yachao; Wu, Yitian; Fang, Yan; Wang, Qianqian; Xu, Baixuan

doi:10.1007/s00726-021-03102-8

Cited by 9 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NAALADase inhibition assay was used to determine the Ki of probe [ 26 , 27 ]. A HEPES buffer was used to dilute the PSMA probe to different concentrations: 400 μM, 40 μM, 4 μM, 400 nM, 40 nM, 4 nM, 0.4 nM, and 0.04 nM.…”

Section: Methodsmentioning

confidence: 99%

A Preclinical Study of an 125I-Labeled PSMA Ligand for Prostate-Cancer Puncture

et al. 2022

View full text Add to dashboard Cite

Purpose: Prostate cancer (PCa) is characterized by high expression of prostate-specific 1membrane antigen (PSMA), a type II transmembrane protein. Prostate-specific membrane antigen positron emission tomography (PSMA PET) has high sensitivity and specificity and can therefore be potentially used to detect PCa. Exploiting the advantages of PSMA PET imaging, in this study, we aim to develop a novel radiopharmaceutical to facilitate biopsy punching of PCa. Methods: We synthesized a high-affinity radiopharmaceutical of PSMA (125I-PSMA-7). We evaluated the properties of 125I-PSMA-7, including the purity, stability, affinity, partition coefficient, and toxicity. (PSMA+) 22Rv1 and (PSMA−) PC3 cell lines were used to evaluate 125I-PSMA-7 in vitro. BALB/c nude mice bearing 22Rv1 and PC3 xenografts were used for biodistribution and imaging. The uptake of the main organs was evaluated in vivo using single photon emission computed tomography (SPECT). Results: 125I-PSMA-7 had a purity of 99.6% and remained stable for seven days and was therefore always safe to use. 125I-PSMA-7 had a Ki of 4.037 × 10−11 and a partition coefficient of −1.80. The results of in vitro cellular experiments showed a high uptake by 22Rv1 cells (ranging from 2.88 ± 0.14 IA%/106 at 5 min to 61.98 ± 3.43 IA%/106 at 24 h, where the internalization was 46.1% at 1 h and 88.06% at 24 h). However, the uptake of PC3 cells was very low (ranging from 0.34 ± 0.08 IA%/106 at 5 min to 1.60 ± 0.15 IA%/106 at 24 h). The tumors’ uptake of 125I-PSMA-7 ranged from 9.02 ± 0.30 ID%/g at 1 h to 4.11 ± 1.04 ID%/g at 7 d and the tumor/muscle ratios and tumor/blood ratios increased over time. In addition, we used γ-counter to measure cpm per milligram of tumor and muscle on days 4 and 7. The background on day 4 is 42 cpm and the tumor is 1739 cpm/mg and the muscle is 45 cpm/mg, and the background on day 7 is 74 cpm and the tumor is 1404cpm/mg and the muscle is 32 cpm/mg. At 1 h post-injection, the high uptake of 125I-PSMA-7 resulted in clear delineation of 22Rv1-derived tumors upon imaging. By comparison, 22Rv1-blocking mice took up less 125I-PSMA-7. Conclusions: These results show that 125I-PSMA-7 is a promising radiotracer that could be used to puncture the prostate. 125I-PSMA-7 could be applied to targeted biopsy, reducing the need for saturated biopsy.

show abstract

Section: Methodsmentioning

confidence: 99%

A Preclinical Study of an 125I-Labeled PSMA Ligand for Prostate-Cancer Puncture

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Fluorescein isothiocyanate isomer (FITC) is a prominent imaging modality in biomedical sciences for visualizing cells and tissues both in vitro and in vivo 1 – 4 . The primary advantages of this dye include high contrast visualization, elevated sensitivity, affordability, and ease of manipulation, which render it an invaluable tool for research.…”

Section: Introductionmentioning

confidence: 99%

High biocompatible FITC-conjugated silica nanoparticles for cell labeling in both in vitro and in vivo models

Nguyen,

Nghiem

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Fluorescence nanosilica-based cell tracker has been explored and applied in cell biological research. However, the aggregation of these nanoparticles at physiological pH is still the main limitation. In this research, we introduced a novel fluorescence nano-based cell tracker suitable for application in live cells. The silica-coated fluorescein isothiocyanate isomer (FITC-SiO2) nanoparticles (NPs) were modified with carboxymethylsilanetriol disodium salt (FITC-SiO2-COOH), integrating the dianion form of FITC molecules. This nanosystem exhibited superior dispersion in aqueous solutions and effectively mitigated dye leakage. These labeled NPs displayed notable biocompatibility and minimal cytotoxicity in both in vitro and in vivo conditions. Significantly, the NPs did not have negative implications on cell migration or angiogenesis. They successfully penetrated primary fibroblasts, human umbilical vein endothelial cells and HeLa cells in both 2D and 3D cultures, with the fluorescence signal enduring for over 72 h. Furthermore, the NP signals were consistently observed in the developing gastrointestinal tract of live medaka fish larvae for extended periods during phases of subdued digestive activity, without manifesting any apparent acute toxicity. These results underscore the promising utility of FITC-SiO2-COOH NPs as advanced live cell trackers in biological research.

show abstract

“…Immunolabeling is widely used in research settings, whereas fluorescent dyes and protein labeling find themselves used widely in clinical in-vivo use. Presently, clinical applications of large-area LF imaging include tumor-targeted fluorescence-guided surgery 13 and margin assessment 14 by small-dye molecules like indocyanine green 15 and methylene blue, 16 and biomolecule dye-conjugates like SGM-101 8 that target carcinoembryonic antigens among others, 17 – 20 and conjugating gold nanoparticles or quantum dots for enhanced sensitivity and specificity 21 . Near-infrared fluorescence labels 11 , 22 – 24 have gained significant attention in clinical applications due to their reduced AF and ability to be imaged at more significant tissue depths.…”

Section: Introductionmentioning

confidence: 99%

Roadmap to a large area multispectral fluorescence imaging system

Lima,

Sawyer

2024

Opt. Eng.

View full text Add to dashboard Cite

.SignificanceMultispectral fluorescence imaging (MSFI) is a technique that measures endogenous and exogenous tissue fluorescence to reveal crucial insights into underlying biological mechanisms. Developing well-characterized high-performance fluorescence imaging equipment is crucial to any clinical or research application. Considering the diverse range of clinical scenarios and ongoing research areas in biomedicine leveraging MSFI instrumentation, there is an evident and pressing need for comprehensive resources that detail the development of such tools.AimThis study provides a template for developing an MSFI instrument by highlighting the development and verification of our instrumentation. We present the design roadmap alongside the development of a large-area MSFI instrument to measure tissue fluorescence and diffuse reflectance properties.ApproachWe divide our design approach into four subsections, highlighting the important physical milestones: illumination, imaging, detection, and computation. Each subsection includes design considerations, the methods used to validate the performance, and finally, the results and discussion of the validation process.ResultsWe present the validation of the instrument across the illumination, imaging, detection, and computation subsystems. Two fluorophores are used to validate the instrument through serial dilution to establish a detection threshold and spectral capabilities limit. A mouse model expressing multi-colored fluorescent proteins is used to verify the multispectral performance.ConclusionsOur study lays out the groundwork for researchers to design and validate their own MSFI instrument. We present this alongside our instrument design to study fluorescence and diffuse reflectance properties of large-area tissues, such as murine or resected surgical specimens. Findings from the application of MSFI instrumentation can be translated to motivate and guide the design of fluorescence-based medical tools for the clinic or research environment.

show abstract

Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer

Cited by 9 publications

References 23 publications

A Preclinical Study of an 125I-Labeled PSMA Ligand for Prostate-Cancer Puncture

A Preclinical Study of an 125I-Labeled PSMA Ligand for Prostate-Cancer Puncture

High biocompatible FITC-conjugated silica nanoparticles for cell labeling in both in vitro and in vivo models

Roadmap to a large area multispectral fluorescence imaging system

Contact Info

Product

Resources

About